{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:38:31Z","timestamp":1784734711136,"version":"3.55.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Acute severe ulcerative colitis (ASUC) remains a high-risk condition with suboptimal clinical outcomes despite advancements in diagnostics, prognostication, and therapies. This review synthesizes recent evidence to address critical gaps in care, focusing on optimizing medical strategies to reduce colectomy rates and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent studies have identified novel biomarkers and predictive models for stratifying patients as high-risk for colectomy. Several emerging therapeutic strategies to optimize care have also been explored. Intensified infliximab dosing has not consistently shown improved clinical outcomes across all patients with ASUC, though it may benefit a subset of patients with unfavorable pharmacokinetics. Furthermore, Janus kinase inhibitors have shown promise in reducing colectomy rates, offering a potential alternative for select patients; however, supporting evidence remains preliminary. Despite these advancements, colectomy remains exceedingly common but continues to serve as a critical intervention to reduce complications and mortality. This underscores the therapeutic efficacy ceiling that still exists in our current approach to ASUC in 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Modern ASUC management prioritizes rapid risk stratification (using clinical, endoscopic, and biomarker data) and patient-tailored advanced therapy selection. Future strategies should focus on conducting rigorous trials of emerging agents in comparison to our current protocols, while integrating real-time, personalized, and dynamic prognostic tools to reduce heterogeneity in treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11894-025-01025-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:44:10Z","timestamp":1767782650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Managing Acute Severe Ulcerative Colitis in 2025 and Beyond"],"prefix":"10.1007","volume":"28","author":[{"given":"Manjeet Kumar","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Adeel","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Aaron","family":"Berinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"4","key":"1025_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MOG.0000000000000953","volume":"01","author":"JA Berinstein","year":"2023","unstructured":"Berinstein JA, Aintabi D, Higgins PDR. In-hospital management of inflammatory bowel disease. Curr Opin Gastroenterol. 2023;01(4):274\u201386. https:\/\/doi.org\/10.1097\/MOG.0000000000000953.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4947","key":"1025_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","volume":"2","author":"SC Truelove","year":"1955","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041\u20138.","journal-title":"Br Med J"},{"key":"1025_CR3","doi-asserted-by":"publisher","unstructured":"Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L. Acute severe ulcerative colitis trials: the past, the present and the future. Gut. 2024(10). https:\/\/doi.org\/10.1136\/gutjnl-2024-332489.","DOI":"10.1136\/gutjnl-2024-332489"},{"issue":"9857","key":"1025_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(12)61084-8.","journal-title":"Lancet"},{"issue":"7","key":"1025_CR5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G J\u00e4rnerot","year":"2005","unstructured":"J\u00e4rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805\u201311.","journal-title":"Gastroenterology"},{"key":"1025_CR6","doi-asserted-by":"publisher","unstructured":"Vuyyuru SK, Nardone OM, Jairath V. Predicting outcome after acute severe ulcerative colitis: a contemporary review and areas for future research. J Clin Med. 2024(15). https:\/\/doi.org\/10.3390\/jcm13154509.","DOI":"10.3390\/jcm13154509"},{"issue":"7","key":"1025_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","volume":"01","author":"A Singh","year":"2024","unstructured":"Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024;01(7):1365\u201372. https:\/\/doi.org\/10.14309\/ajg.0000000000002635.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1025_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf013","volume":"7","author":"N Narula","year":"2025","unstructured":"Narula N, Pray C, Hamam H, et al. Tofacitinib for hospitalized acute severe ulcerative colitis management (the TRIUMPH study). Crohn\u2019s & Colitis 360. 2025;7(1):otaf013. https:\/\/doi.org\/10.1093\/crocol\/otaf013.","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"3","key":"1025_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1025_CR10","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","volume":"21","author":"MJ Buie","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, et al. Global hospitalization trends for crohn\u2019s disease and ulcerative colitis in the 21st century: A systematic review with Temporal analyses. Clin Gastroenterol Hepatol Aug. 2023;21(9):2211\u201321. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.030.","journal-title":"Clin Gastroenterol Hepatol Aug"},{"issue":"4","key":"1025_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","volume":"4","author":"LC Dinesen","year":"2010","unstructured":"Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431\u20137. https:\/\/doi.org\/10.1016\/j.crohns.2010.02.001.","journal-title":"J Crohns Colitis"},{"issue":"Supplement2","key":"1025_CR12","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","volume":"30","author":"B Caron","year":"2024","unstructured":"Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohns Colitis Oct. 2024;30(Supplement2):ii3\u201315. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae082.","journal-title":"J Crohns Colitis Oct"},{"issue":"9","key":"1025_CR13","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1097\/MIB.0b013e31828c84c5","volume":"19","author":"S Samuel","year":"2013","unstructured":"Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis Aug. 2013;19(9):1858\u201366. https:\/\/doi.org\/10.1097\/MIB.0b013e31828c84c5.","journal-title":"Inflamm Bowel Dis Aug"},{"issue":"1","key":"1025_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40258-018-0432-4","volume":"02","author":"F Xu","year":"2019","unstructured":"Xu F, Liu Y, Wheaton AG, Rabarison KM, Croft JB. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States. Appl Health Econ Health Policy. 2019;02(1):77\u201391. https:\/\/doi.org\/10.1007\/s40258-018-0432-4.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"1025_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2468-1253(19)30013-5","volume":"4","author":"JA King","year":"2019","unstructured":"King JA, Underwood FE, Panaccione N, et al. Trends in hospitalisation rates for inflammatory bowel disease in Western versus newly industrialised countries: a population-based study of countries in the organisation for economic Co-operation and development. Lancet Gastroenterol Hepatol Apr. 2019;4(4):287\u201395. https:\/\/doi.org\/10.1016\/S2468-1253(19)30013-5.","journal-title":"Lancet Gastroenterol Hepatol Apr"},{"issue":"3800","key":"1025_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/bmj.2.3800.812","volume":"2","author":"TL Hardy","year":"1933","unstructured":"Hardy TL, Bulmer E. ULCERATIVE COLITIS: A SURVEY OF NINETY-FIVE CASES. Br Med J. 1933;2(3800):812\u20135. https:\/\/doi.org\/10.1136\/bmj.2.3800.812.","journal-title":"Br Med J"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/BTT.S179006","volume":"13","author":"A Viscido","year":"2019","unstructured":"Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics. 2019;13:23\u201331. https:\/\/doi.org\/10.2147\/BTT.S179006.","journal-title":"Biologics"},{"issue":"3","key":"1025_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2008.01.004","volume":"134","author":"GG Kaplan","year":"2008","unstructured":"Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology Mar. 2008;134(3):680\u20137. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.004.","journal-title":"Gastroenterology Mar"},{"issue":"4","key":"1025_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1053\/j.gastro.2015.06.001","volume":"149","author":"S Singh","year":"2015","unstructured":"Singh S, Al-Darmaki A, Frolkis AD, et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149(4):928\u201337. https:\/\/doi.org\/10.1053\/j.gastro.2015.06.001.","journal-title":"Gastroenterology"},{"issue":"3","key":"1025_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/bjs.6874","volume":"97","author":"J Randall","year":"2010","unstructured":"Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404\u20139. https:\/\/doi.org\/10.1002\/bjs.6874.","journal-title":"Br J Surg"},{"issue":"1","key":"1025_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.15592","volume":"51","author":"C Dong","year":"2020","unstructured":"Dong C, Metzger M, Holsb\u00f8 E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2020;51(1):8\u201333. https:\/\/doi.org\/10.1111\/apt.15592.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1025_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1095-9","volume":"09","author":"J Constantin","year":"2019","unstructured":"Constantin J, Atanasov P, Wirth D, Borsi A. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterol. 2019;09(1):179. https:\/\/doi.org\/10.1186\/s12876-019-1095-9.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"1025_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1572-0241.2003.07378.x","volume":"98","author":"T Longobardi","year":"2003","unstructured":"Longobardi T, Jacobs P, Wu L, Bernstein CN. Work losses related to inflammatory bowel disease in Canada: results from a national population health survey. Am J Gastroenterol. 2003;98(4):844\u20139. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07378.x.","journal-title":"Am J Gastroenterol"},{"key":"1025_CR24","doi-asserted-by":"publisher","unstructured":"Taft TH, Quinton S, Jedel S, Simons M, Mutlu EA, Hanauer SB. Posttraumatic stress in patients with inflammatory bowel disease: prevalence and relationships to patient-reported outcomes. Inflamm Bowel Dis. 2022(5). https:\/\/doi.org\/10.1093\/ibd\/izab152.","DOI":"10.1093\/ibd\/izab152"},{"issue":"3","key":"1025_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apt.16445","volume":"54","author":"RCA van Linschoten","year":"2021","unstructured":"van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021;54(3):234\u201348. https:\/\/doi.org\/10.1111\/apt.16445.","journal-title":"Aliment Pharmacol Ther"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"S449","DOI":"10.14309\/01.ajg.0000705532.18543.be","volume":"115","author":"Q Cai","year":"2020","unstructured":"Cai Q, Ding Z, Teeple A, Gowda P, Muser E. S0871\u2003costs of inflammatory bowel disease-related hospitalizations and surgeries: a retrospective analysis in a commercially insured population. Am J Gastroenterol. 2020;115:S449\u2013S449. https:\/\/doi.org\/10.14309\/01.ajg.0000705532.18543.be.","journal-title":"Am J Gastroenterol"},{"key":"1025_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0680","author":"S Vuyyuru","year":"2024","unstructured":"Vuyyuru S, Alphonsus L, De Silva TA. P550 Short and long-term outcomes after acute severe ulcerative colitis in adults: a 12 year Canadian experience in the post biologic era. J Crohns Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0680.","journal-title":"J Crohns Colitis"},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"204062231982559","DOI":"10.1177\/2040622319825595","volume":"10","author":"A Vasudevan","year":"2019","unstructured":"Vasudevan A, Arachchi A, Scanlon C, Greenhalgh J, Van Langenberg DR. A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving Infliximab. Ther Adv Chronic Dis. 2019;10:2040622319825595. https:\/\/doi.org\/10.1177\/2040622319825595.","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"1025_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/jgh3.12933","volume":"7","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, Lo SW, Cheong R, et al. Factors associated with long-term healthcare expense and steroid exposure in patients admitted with acute severe ulcerative colitis. JGH Open. 2023;7(7):482\u20136. https:\/\/doi.org\/10.1002\/jgh3.12933.","journal-title":"JGH Open"},{"issue":"11","key":"1025_CR30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","volume":"13","author":"P Hindryckx","year":"2016","unstructured":"Hindryckx P, Jairath V, D\u2019Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol Nov. 2016;13(11):654\u201364. https:\/\/doi.org\/10.1038\/nrgastro.2016.116.","journal-title":"Nat Rev Gastroenterol Hepatol Nov"},{"issue":"11","key":"1025_CR31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/ibd.21293","volume":"16","author":"T Haritunians","year":"2010","unstructured":"Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16(11):1830\u201340. https:\/\/doi.org\/10.1002\/ibd.21293.","journal-title":"Inflamm Bowel Dis"},{"issue":"22","key":"1025_CR32","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1001\/jama.2024.20429","volume":"10","author":"MV Vestergaard","year":"2024","unstructured":"Vestergaard MV, N\u00f8hr AK, Allin KH, et al. HLA-DRB1*01:03 and severe ulcerative colitis. JAMA Dec. 2024;10(22):1941\u20133. https:\/\/doi.org\/10.1001\/jama.2024.20429.","journal-title":"JAMA Dec"},{"key":"1025_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123144","author":"G \u015awirkosz","year":"2023","unstructured":"\u015awirkosz G, Szczygie\u0142 A, Logo\u0144 K, Wrze\u015bniewska M, Gomu\u0142ka K. The role of the microbiome in the pathogenesis and treatment of ulcerative colitis-a literature review. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11123144.","journal-title":"Biomedicines"},{"issue":"1","key":"1025_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3748\/wjg.v24.i1.5","volume":"07","author":"ZH Shen","year":"2018","unstructured":"Shen ZH, Zhu CX, Quan YS. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;07(1):5\u201314. https:\/\/doi.org\/10.3748\/wjg.v24.i1.5.","journal-title":"World J Gastroenterol"},{"key":"1025_CR35","doi-asserted-by":"publisher","unstructured":"Basha OM, Hafez RA, Salem SM, Anis RH, Hanafy AS. Impact of gut Microbiome alteration in ulcerative colitis patients on disease severity and outcome. Clin Exp Med. 2023;23(5):1763\u201372. https:\/\/doi.org\/10.1007\/s10238-022-00917-x.","DOI":"10.1007\/s10238-022-00917-x"},{"issue":"May","key":"1025_CR36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s12276-021-00617-8","volume":"53","author":"J Fang","year":"2021","unstructured":"Fang J, Wang H, Zhou Y, Zhang H, Zhou H, Zhang X. Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis. Exp Mol Med. 2021;53(May):772\u201387. https:\/\/doi.org\/10.1038\/s12276-021-00617-8.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1025_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcmgh.2016.10.004","volume":"3","author":"A Shawki","year":"2017","unstructured":"Shawki A, McCole DF. Mechanisms of intestinal epithelial barrier dysfunction by Adherent-Invasive. Cell Mol Gastroenterol Hepatol Jan. 2017;3(1):41\u201350. https:\/\/doi.org\/10.1016\/j.jcmgh.2016.10.004.","journal-title":"Cell Mol Gastroenterol Hepatol Jan"},{"issue":"2","key":"1025_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2007.128231","volume":"57","author":"AN Ananthakrishnan","year":"2008","unstructured":"Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205\u201310. https:\/\/doi.org\/10.1136\/gut.2007.128231.","journal-title":"Gut"},{"issue":"8","key":"1025_CR39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.cgh.2019.12.036","volume":"19","author":"G Le Baut","year":"2021","unstructured":"Le Baut G, Kirchgesner J, Amiot A, et al. A scoring system to determine patients\u2019 risk of colectomy within 1 year after hospital admission for acute severe ulcerative colitis. Clin Gastroenterol Hepatol Aug. 2021;19(8):1602\u2013e16101. https:\/\/doi.org\/10.1016\/j.cgh.2019.12.036.","journal-title":"Clin Gastroenterol Hepatol Aug"},{"issue":"10S","key":"1025_CR40","doi-asserted-by":"publisher","first-page":"S826","DOI":"10.14309\/01.ajg.0000953984.31997.49","volume":"118","author":"EJ Spartz","year":"2023","unstructured":"Spartz EJ, Roney A, DeDecker L, et al. S1086\u2003The impact of intravenous corticosteroid therapy in hospitalized patients with inflammatory bowel disease with clostridioides difficile infection. Official J Am Coll Gastroenterol | ACG. 2023;118(10S):S826\u20137. https:\/\/doi.org\/10.14309\/01.ajg.0000953984.31997.49.","journal-title":"Official J Am Coll Gastroenterol | ACG"},{"issue":"3","key":"1025_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad032","volume":"5","author":"S Sharma","year":"2023","unstructured":"Sharma S, Li DK, Levine LJ. Early flexible sigmoidoscopy improves clinical outcomes in acute severe ulcerative colitis. Crohn\u2019s & Colitis 360. 2023;5(3):otad032. https:\/\/doi.org\/10.1093\/crocol\/otad032.","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"12","key":"1025_CR42","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1038\/ctg.2016.61","volume":"01","author":"K Obi","year":"2016","unstructured":"Obi K, Hinton A, Sobotka L, et al. Early sigmoidoscopy or colonoscopy is associated with improved hospital outcomes in ulcerative Colitis-Related hospitalization. Clin Transl Gastroenterol Dec. 2016;01(12):e203. https:\/\/doi.org\/10.1038\/ctg.2016.61.","journal-title":"Clin Transl Gastroenterol Dec"},{"issue":"4","key":"1025_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab080","volume":"3","author":"AS Bali","year":"2021","unstructured":"Bali AS, Picco MF, Hashash JG, Farraye FA, Kr\u00f6ner PT. Time to flexible sigmoidoscopy or colonoscopy in patients admitted with ulcerative colitis has decreased from 2012 to 2018. Crohn\u2019s & Colitis 360. 2021;3(4):otab080. https:\/\/doi.org\/10.1093\/crocol\/otab080.","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"suppl1","key":"1025_CR44","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/ecco-jcc\/jju027.204","volume":"9","author":"P Daffra","year":"2015","unstructured":"Daffra P, Aldecoa I, Ordas I, et al. P086. The presence of the Epstein-Barr virus is associated to a higher colectomy requirement in patients with ulcerative colitis. J Crohn\u2019s Colitis. 2015;9(suppl1):S121\u2013121. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju027.204.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1025_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.humpath.2018.08.001","volume":"82","author":"MK Pezhouh","year":"2018","unstructured":"Pezhouh MK, Miller JA, Sharma R, et al. Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in situ hybridization. Hum Pathol Dec. 2018;82:187\u201392. https:\/\/doi.org\/10.1016\/j.humpath.2018.08.001.","journal-title":"Hum Pathol Dec"},{"issue":"10","key":"1025_CR46","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/ecco-jcc\/jjw071","volume":"10","author":"E Zag\u00f3rowicz","year":"2016","unstructured":"Zag\u00f3rowicz E, Bugajski M, Wieszczy P, Pietrzak A, Magdziak A, Mr\u00f3z A. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of Cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205\u201311. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw071.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1025_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"01","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis Feb. 2019;01(2):144\u201364. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113.","journal-title":"J Crohns Colitis Feb"},{"issue":"1","key":"1025_CR48","doi-asserted-by":"publisher","first-page":"S-1560","DOI":"10.1016\/S0016-5085(25)04453-1","volume":"169","author":"P Gu","year":"2025","unstructured":"Gu P, Dube S, Khan A. Tu1924: INCREASED VISCERAL ADIPOSE TISSUE (VAT) IS ASSOCIATED WITH POOR RESPONSE TO INFLIXIMAB SALVAGE THERAPY IN ACUTE SEVERE ULCERATIVE COLITIS (ASUC). Gastroenterology. 2025;169(1):S-1560. https:\/\/doi.org\/10.1016\/S0016-5085(25)04453-1.","journal-title":"Gastroenterology"},{"issue":"3","key":"1025_CR49","first-page":"147","volume":"19","author":"NK Cleveland","year":"2023","unstructured":"Cleveland NK, Picker EA, Dolinger MT, Rubin DT. The arrival of intestinal ultrasound for inflammatory bowel disease care in the United States. Gastroenterol hepatol (N Y). 2023;19(3):147\u201354.","journal-title":"Gastroenterol hepatol (N Y)"},{"issue":"Supplement1","key":"1025_CR50","doi-asserted-by":"publisher","first-page":"i2079","DOI":"10.1093\/ecco-jcc\/jjae190.1311","volume":"19","author":"E Zacharopoulou","year":"2025","unstructured":"Zacharopoulou E, Bellou G, Palatianou M, et al. P1137 prognostic value of intestinal ultrasound (IUS) in patients with acute severe ulcerative colitis (ASUC) \u2013 A single center experience. J Crohn\u2019s Colitis. 2025;19(Supplement1):i2079\u20132079. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1311.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"Supplement1","key":"1025_CR51","doi-asserted-by":"publisher","first-page":"i912","DOI":"10.1093\/ecco-jcc\/jjae190.0585","volume":"19","author":"S Criado","year":"2025","unstructured":"Criado S, Su\u00e1rez Ferrer C, Poza Cord\u00f3n J, et al. P0411 utility of intestinal ultrasound as a predictor of severe ulcerative colitis response to treatment. J Crohn\u2019s Colitis. 2025;19(Supplement1):i912\u20134. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0585.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1025_CR52","doi-asserted-by":"publisher","unstructured":"Ilvemark JFKF, Wilkens R, Thielsen P, et al. Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalised patients with severe ulcerative colitis. J Crohns Colitis. 2022(11). https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac083.","DOI":"10.1093\/ecco-jcc\/jjac083"},{"issue":"7","key":"1025_CR53","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/ecco-jcc\/jjaa265","volume":"05","author":"V Gupta","year":"2021","unstructured":"Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting outcome in acute severe colitis-controversies in clinical practice in 2021. J Crohns Colitis. 2021;05(7):1211\u201321. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa265.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1025_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab029","volume":"3","author":"S Weissman","year":"2021","unstructured":"Weissman S, Sharma S, Fung BM, et al. Increased mortality and healthcare costs upon hospital readmissions of ulcerative colitis flares: a large population-based cohort study. Crohn\u2019s & Colitis 360. 2021;3(3):otab029. https:\/\/doi.org\/10.1093\/crocol\/otab029.","journal-title":"Crohn\u2019s & Colitis 360"},{"issue":"1","key":"1025_CR55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1572-0241.2006.00330.x","volume":"101","author":"CN Bernstein","year":"2006","unstructured":"Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006;101(1):110\u20138. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00330.x.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1025_CR56","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/apt.12473","volume":"38","author":"RW Lynch","year":"2013","unstructured":"Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the united Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38(8):935\u201345. https:\/\/doi.org\/10.1111\/apt.12473.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1025_CR57","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ibd\/izaa088","volume":"15","author":"RK Grant","year":"2021","unstructured":"Grant RK, Jones GR, Plevris N, et al. The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm Bowel Dis. 2021;15(4):451\u20137. https:\/\/doi.org\/10.1093\/ibd\/izaa088.","journal-title":"Inflamm Bowel Dis"},{"key":"1025_CR58","doi-asserted-by":"publisher","unstructured":"Zheng J, Fan Z, Li C, Wang D, Zhang S, Chen R. Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2024(1). https:\/\/doi.org\/10.1136\/bmjgast-2024-001587.","DOI":"10.1136\/bmjgast-2024-001587"},{"issue":"2","key":"1025_CR59","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3892\/etm.2020.8861","volume":"20","author":"R Ma","year":"2020","unstructured":"Ma R, Meng R, Zhang X, Sun Z, Lei Y. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med. 2020;20(2):1498\u2013504. https:\/\/doi.org\/10.3892\/etm.2020.8861.","journal-title":"Exp Ther Med"},{"issue":"6","key":"1025_CR60","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/MCG.0000000000000884","volume":"52","author":"DJ Gibson","year":"2018","unstructured":"Gibson DJ, Hartery K, Doherty J, et al. CRP\/Albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol Jul. 2018;52(6):e48\u201352. https:\/\/doi.org\/10.1097\/MCG.0000000000000884.","journal-title":"J Clin Gastroenterol Jul"},{"issue":"10","key":"1025_CR61","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","volume":"15","author":"GT Ho","year":"2004","unstructured":"Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;15(10):1079\u201387. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.01945.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1025_CR62","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ajg.2008.119","volume":"104","author":"GT Ho","year":"2009","unstructured":"Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104(3):673\u20138. https:\/\/doi.org\/10.1038\/ajg.2008.119.","journal-title":"Am J Gastroenterol"},{"key":"1025_CR63","doi-asserted-by":"publisher","unstructured":"Sasidharan S, Sasson AN, Shannon KM, Ananthakrishnan AN. Fecal calprotectin is a predictor of need for rescue therapy in hospitalized severe colitis. Inflamm Bowel Dis. 2022(12). https:\/\/doi.org\/10.1093\/ibd\/izac011.","DOI":"10.1093\/ibd\/izac011"},{"issue":"1","key":"1025_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103\u201310. https:\/\/doi.org\/10.1016\/j.cgh.2006.09.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"1025_CR65","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","volume":"138","author":"D Turner","year":"2010","unstructured":"Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282\u201391. https:\/\/doi.org\/10.1053\/j.gastro.2010.02.047.","journal-title":"Gastroenterology"},{"key":"1025_CR66","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.14309\/01.ajg.0000723072.98473.28","volume":"115","author":"S Deloshaan","year":"2020","unstructured":"Deloshaan S, Pradeep KR, Dheeraj S, et al. P069\u2003admission steroid use, serum albumin and endoscopic severity predict intravenous steroid failure in patients with acute severe ulcerative colitis. Am J Gastroenterol. 2020;115:S18\u2013S18. https:\/\/doi.org\/10.14309\/01.ajg.0000723072.98473.28.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1025_CR67","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/apt.17731","volume":"58","author":"M Kayal","year":"2023","unstructured":"Kayal M, Meringer H, Martin L, Colombel JF. Systematic review: scores used to predict outcomes in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2023;58(10):974\u201383. https:\/\/doi.org\/10.1111\/apt.17731.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1025_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2022-327533","volume":"72","author":"A Adams","year":"2023","unstructured":"Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut. 2023;72(3):433\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2022-327533.","journal-title":"Gut"},{"issue":"6","key":"1025_CR69","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905\u201310.","journal-title":"Gut"},{"issue":"11","key":"1025_CR70","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/apt.13614","volume":"43","author":"RW Lynch","year":"2016","unstructured":"Lynch RW, Churchhouse AM, Protheroe A, Arnott ID, Group UIAS. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther. 2016;43(11):1132\u201341. https:\/\/doi.org\/10.1111\/apt.13614.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1025_CR71","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/00042737-199810000-00003","volume":"10","author":"SC Lindgren","year":"1998","unstructured":"Lindgren SC, Flood LM, Kilander AF, L\u00f6fberg R, Persson TB, Sj\u00f6dahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol Oct. 1998;10(10):831\u20135. https:\/\/doi.org\/10.1097\/00042737-199810000-00003.","journal-title":"Eur J Gastroenterol Hepatol Oct"},{"issue":"3","key":"1025_CR72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12664-021-01217-0","volume":"41","author":"P Sahu","year":"2022","unstructured":"Sahu P, Jain S, Kedia S, et al. Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian J Gastroenterol. 2022;41(3):273\u201383. https:\/\/doi.org\/10.1007\/s12664-021-01217-0.","journal-title":"Indian J Gastroenterol"},{"issue":"11","key":"1025_CR73","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ecco-jcc\/jjx084","volume":"27","author":"S Jain","year":"2017","unstructured":"Jain S, Kedia S, Bopanna S, et al. Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis: prospective cohort study. J Crohns Colitis. 2017;27(11):1309\u201316. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx084.","journal-title":"J Crohns Colitis"},{"issue":"7866","key":"1025_CR74","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/s0140-6736(74)90552-2","volume":"01","author":"SC Truelove","year":"1974","unstructured":"Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;01(7866):1067\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(74)90552-2.","journal-title":"Lancet"},{"issue":"2","key":"1025_CR75","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s10620-019-05668-6","volume":"02","author":"AC Moore","year":"2020","unstructured":"Moore AC, Bressler B. Acute severe ulcerative colitis: the Oxford criteria no longer predict in-hospital colectomy rates. Dig Dis Sci. 2020;02(2):576\u201380. https:\/\/doi.org\/10.1007\/s10620-019-05668-6.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"1025_CR76","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1007\/s10620-022-07490-z","volume":"67","author":"A Caplan","year":"2022","unstructured":"Caplan A, McConnell R, Velayos F, Mahadevan U, Lewin S. Delayed initiation of rescue therapy associated with increased length of stay in acute severe ulcerative colitis. Dig Dis Sci. 2022;67(12):5455\u201361. https:\/\/doi.org\/10.1007\/s10620-022-07490-z.","journal-title":"Dig Dis Sci"},{"issue":"Supplement1","key":"1025_CR77","doi-asserted-by":"publisher","first-page":"i1489","DOI":"10.1093\/ecco-jcc\/jjae190.0945","volume":"19","author":"M Mohamedrashed","year":"2025","unstructured":"Mohamedrashed M, Yogakanthi S, Xu C, et al. P0771 early Infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis. J Crohn\u2019s Colitis. 2025;19(Supplement1):i1489\u201390. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0945.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"26","key":"1025_CR78","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841\u20135. https:\/\/doi.org\/10.1056\/NEJM199406303302601.","journal-title":"N Engl J Med"},{"issue":"4","key":"1025_CR79","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/s0016-5085(03)01214-9","volume":"125","author":"G Van Assche","year":"2003","unstructured":"Van Assche G, D\u2019Haens G, Noman M. Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D\u2019Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D\u2019Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy. Gastroenterology. 2003;125(4):1025\u201331. https:\/\/doi.org\/10.1016\/s0016-5085(03)01214-9.","journal-title":"Gastroenterology"},{"issue":"6","key":"1025_CR80","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","volume":"4","author":"DN Moskovitz","year":"2006","unstructured":"Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760\u20135. https:\/\/doi.org\/10.1016\/j.cgh.2006.04.001.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1025_CR81","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","volume":"17","author":"S Campbell","year":"2005","unstructured":"Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17(1):79\u201384. https:\/\/doi.org\/10.1097\/00042737-200501000-00016.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"1025_CR82","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","volume":"103","author":"MB Sternthal","year":"2008","unstructured":"Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103(4):937\u201343. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01718.x.","journal-title":"Am J Gastroenterol"},{"key":"1025_CR83","doi-asserted-by":"publisher","unstructured":"Gordon BL, Battat R. Therapeutic drug monitoring of Infliximab in acute severe ulcerative colitis. J Clin Med. 2023;10(10). https:\/\/doi.org\/10.3390\/jcm12103378.","DOI":"10.3390\/jcm12103378"},{"issue":"2","key":"1025_CR84","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of Infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology Aug. 2015;149(2):350. 5.e2.","journal-title":"Gastroenterology Aug"},{"issue":"4","key":"1025_CR85","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of Infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360. https:\/\/doi.org\/10.1097\/MIB.0000000000001043.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"1025_CR86","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247\u201359. https:\/\/doi.org\/10.1097\/MIB.0000000000000212.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1025_CR87","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","volume":"13","author":"DJ Gibson","year":"2015","unstructured":"Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated Infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol Feb. 2015;13(2):330\u2013e3351. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.041.","journal-title":"Clin Gastroenterol Hepatol Feb"},{"issue":"6","key":"1025_CR88","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/flgastro-2019-101335","volume":"11","author":"DJ Gibson","year":"2020","unstructured":"Gibson DJ, Doherty J, McNally M, et al. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol. 2020;11(6):441\u20137. https:\/\/doi.org\/10.1136\/flgastro-2019-101335.","journal-title":"Frontline Gastroenterol"},{"key":"1025_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05957-0","author":"SM Govani","year":"2019","unstructured":"Govani SM, Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Hardiman KM. Use of accelerated induction strategy of Infliximab for ulcerative colitis in hospitalized patients at a tertiary care center. Dig Dis Sci. 2019. https:\/\/doi.org\/10.1007\/s10620-019-05957-0.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1025_CR90","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","volume":"02","author":"N Nalagatla","year":"2019","unstructured":"Nalagatla N, Falloon K, Tran G, et al. Effect of accelerated Infliximab induction on Short- and Long-term outcomes of acute severe ulcerative colitis: A retrospective multicenter study and Meta-analysis. Clin Gastroenterol Hepatol. 2019;02(3):502\u2013e5091. https:\/\/doi.org\/10.1016\/j.cgh.2018.06.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1025_CR91","doi-asserted-by":"publisher","unstructured":"Choy MC, Seah D, Faleck DM, et al. Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflamm Bowel Dis. 2019(7). https:\/\/doi.org\/10.1093\/ibd\/izy383.","DOI":"10.1093\/ibd\/izy383"},{"issue":"11","key":"1025_CR92","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","volume":"9","author":"MC Choy","year":"2024","unstructured":"Choy MC, Li Wai Suen CFD, Con D, et al. Intensified versus standard dose Infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(11):981\u201396. https:\/\/doi.org\/10.1016\/S2468-1253(24)00200-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement1","key":"1025_CR93","doi-asserted-by":"publisher","first-page":"i251","DOI":"10.1093\/ecco-jcc\/jjae190.0130","volume":"19","author":"W Li","year":"2025","unstructured":"Li W, Suen C, Choy MC, Con D, et al. DOP091 early serum Infliximab levels predict outcomes in acute severe ulcerative colitis: results from PREDICT-UC. J Crohn\u2019s Colitis. 2025;19(Supplement1):i251\u2013251. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0130.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"Supplement1","key":"1025_CR94","doi-asserted-by":"publisher","first-page":"i194","DOI":"10.1093\/ecco-jcc\/jjae190.0095","volume":"19","author":"K Gecse","year":"2025","unstructured":"Gecse K, Van Oostrom J, Rietdijk S. DOP056 TDM-based dose-intensification of Infliximab is not superior to standard dosing in patients with acute severe ulcerative colitis: results from the TITRATE study. J Crohns Colitis. 2025;19(Supplement1):i194. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0095.","journal-title":"J Crohns Colitis"},{"key":"1025_CR95","doi-asserted-by":"publisher","unstructured":"Borren NZ, Ananthakrishnan AN. Precision medicine: how multiomics will shape the future of inflammatory bowel disease? Curr Opin Gastroenterol. 2022(4). https:\/\/doi.org\/10.1097\/MOG.0000000000000847.","DOI":"10.1097\/MOG.0000000000000847"},{"issue":"1","key":"1025_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"09","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;09(1):15\u201324. https:\/\/doi.org\/10.1016\/S2468-1253(16)30003-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1025_CR97","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","volume":"67","author":"D Laharie","year":"2018","unstructured":"Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237\u201343. https:\/\/doi.org\/10.1136\/gutjnl-2016-313060.","journal-title":"Gut"},{"issue":"4","key":"1025_CR98","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ajg.2016.7","volume":"111","author":"N Narula","year":"2016","unstructured":"Narula N, Marshall JK, Colombel JF, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111(4):477\u201391. https:\/\/doi.org\/10.1038\/ajg.2016.7.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1025_CR99","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","volume":"21","author":"EV Loftus","year":"2023","unstructured":"Loftus EV, Colombel JF, Takeuchi K, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol Aug. 2023;21(9):2347\u2013e23586. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.029.","journal-title":"Clin Gastroenterol Hepatol Aug"},{"key":"1025_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390","author":"NE Burr","year":"2021","unstructured":"Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021. https:\/\/doi.org\/10.1136\/gutjnl-2021-326390.","journal-title":"Gut"},{"issue":"1","key":"1025_CR101","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","volume":"17","author":"S Hanauer","year":"2019","unstructured":"Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(1):139\u201347. https:\/\/doi.org\/10.1016\/j.cgh.2018.07.009.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1025_CR102","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759\u201373. https:\/\/doi.org\/10.1124\/dmd.113.054940.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1025_CR103","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-019-0378-y","volume":"25","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Trueman S, Othman AA, Han JH, Ju TR, Marroum P. Development of in Vitro-In vivo correlation for Upadacitinib Extended-Release tablet formulation. AAPS J Oct. 2019;25(6):108. https:\/\/doi.org\/10.1208\/s12248-019-0378-y.","journal-title":"AAPS J Oct"},{"key":"1025_CR104","doi-asserted-by":"publisher","unstructured":"Berinstein JA, Karl T, Patel A, et al. Effectiveness of Upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024(7). https:\/\/doi.org\/10.14309\/ajg.0000000000002674.","DOI":"10.14309\/ajg.0000000000002674"},{"issue":"6","key":"1025_CR105","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","volume":"01","author":"BD Constant","year":"2022","unstructured":"Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib salvage therapy for children hospitalized for Corticosteroid- and Biologic-refractory ulcerative colitis. J Pediatr Gastroenterol Nutr. 2022;01(6):724\u201330. https:\/\/doi.org\/10.1097\/MPG.0000000000003616.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"1025_CR106","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","volume":"14","author":"P Kotwani","year":"2020","unstructured":"Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis. 2020;14(7):1026\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa018.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1025_CR107","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","volume":"14","author":"S Honap","year":"2020","unstructured":"Honap S, Chee D, Chapman TP. Real-world effectiveness of Tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385\u201393. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa075.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1025_CR108","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ibd\/izad180","volume":"29","author":"CH Zinger","year":"2023","unstructured":"Zinger CH, Ringel Y, Eitan M, et al. Upadacitinib for acute severe ulcerative colitis. Inflamm Bowel Dis. 2023;29(10):1667\u20139. https:\/\/doi.org\/10.1093\/ibd\/izad180.","journal-title":"Inflamm Bowel Dis"},{"key":"1025_CR109","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad115","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, Tan L, Fernandes R, An YK, Begun J. Upadacitinib salvage therapy for Infliximab experienced patients with acute severe ulcerative colitis. J Crohns Colitis. 2023. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad115.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1025_CR110","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/apt.16463","volume":"08","author":"M Uzzan","year":"2021","unstructured":"Uzzan M, Bresteau C, Laharie D, et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort. Aliment Pharmacol Ther. 2021;08(3):312\u20139. https:\/\/doi.org\/10.1111\/apt.16463.","journal-title":"Aliment Pharmacol Ther"},{"key":"1025_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.038","author":"JA Berinstein","year":"2021","unstructured":"Berinstein JA, Sheehan J, Dias M, et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.038.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"1025_CR112","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","volume":"21","author":"C Steenholdt","year":"2023","unstructured":"Steenholdt C, Dige Ovesen P, Brynskov J, Seidelin JB. Tofacitinib for acute severe ulcerative colitis: a systematic review. J Crohns Colitis. 2023;21(8):1354\u201363. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad036.","journal-title":"J Crohns Colitis"},{"key":"1025_CR113","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae191","author":"JA Damianos","year":"2024","unstructured":"Damianos JA, Osikoya O, Brennan G. Upadacitinib for acute severe ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae191.","journal-title":"Inflamm Bowel Dis"},{"issue":"Supplement1","key":"1025_CR114","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1093\/ibd\/izae282.168","volume":"31","author":"A Patel","year":"2025","unstructured":"Patel A, Hassan SA, Sulbaran M, et al. Efficacy and safety of upadacitinib for acute severe ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2025;31(Supplement1):S72-3. https:\/\/doi.org\/10.1093\/ibd\/izae282.168.","journal-title":"Inflamm Bowel Dis"},{"issue":"Supplement1","key":"1025_CR115","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/ecco-jcc\/jjac190.0033","volume":"17","author":"T Raine","year":"2023","unstructured":"Raine T, Vaja S, Subramanian S, et al. OP33 results of a randomised controlled trial to evaluate Interleukin 1 Blockade with Anakinra in patients with acute severe ulcerative colitis (IASO). J Crohn\u2019s Colitis. 2023;17(Supplement1):i43\u20136. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0033.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"1025_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023765","volume":"15","author":"MG Thomas","year":"2019","unstructured":"Thomas MG, Bayliss C, Bond S, et al. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in acute severe colitis: the IASO trial. BMJ Open. 2019;15(2):e023765. https:\/\/doi.org\/10.1136\/bmjopen-2018-023765.","journal-title":"BMJ Open"},{"issue":"2","key":"1025_CR117","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/2045-9912.311497","volume":"11","author":"X Wu","year":"2021","unstructured":"Wu X, Liang TY, Wang Z, Chen G. The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. Med Gas Res. 2021;11(2):66\u201371. https:\/\/doi.org\/10.4103\/2045-9912.311497.","journal-title":"Med Gas Res"},{"issue":"10","key":"1025_CR118","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41395-018-0005-z","volume":"113","author":"PS Dulai","year":"2018","unstructured":"Dulai PS, Buckey JC, Raffals LE, et al. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol. 2018;113(10):1516\u201323. https:\/\/doi.org\/10.1038\/s41395-018-0005-z.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1025_CR119","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/apt.15984","volume":"52","author":"PS Dulai","year":"2020","unstructured":"Dulai PS, Raffals LE, Hudesman D, et al. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Aliment Pharmacol Ther. 2020;52(6):955\u201363. https:\/\/doi.org\/10.1111\/apt.15984.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1025_CR120","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","volume":"68","author":"EM Berinstein","year":"2023","unstructured":"Berinstein EM, Sheehan JL, Jacob J, et al. Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature. Dig Dis Sci. 2023;68(6):2604\u201323. https:\/\/doi.org\/10.1007\/s10620-023-07837-0.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1025_CR121","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307\u201320. https:\/\/doi.org\/10.1016\/S2468-1253(22)00427-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1025_CR122","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"16","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Garc\u00eda MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023;16(6):972\u201394. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad004.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1025_CR123","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/jpr3.12124","volume":"5","author":"A Dickerson","year":"2024","unstructured":"Dickerson A, Huang JS, Bauman LE. Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Rep. 2024;5(4):447\u201353. https:\/\/doi.org\/10.1002\/jpr3.12124.","journal-title":"JPGN Rep"},{"issue":"1","key":"1025_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542711","volume":"19","author":"D Huynh","year":"2025","unstructured":"Huynh D, Khaing MM, Fernandes RG, et al. Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: A case report. Case Rep Gastroenterol. 2025;19(1):1\u20136. https:\/\/doi.org\/10.1159\/000542711.","journal-title":"Case Rep Gastroenterol"},{"key":"1025_CR125","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab109","author":"R Gilmore","year":"2021","unstructured":"Gilmore R, Hilley P, Srinivasan A, Choy M, De Cruz P. Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. J Crohns Colitis. 2021. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab109.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"1025_CR126","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1093\/ibd\/izab181","volume":"11 15","author":"Q Yang","year":"2021","unstructured":"Yang Q, Chen L, Feng L, et al. Success of cyclosporin and Tofacitinib combination therapy in a patient with severe Steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2021;11 15(12):e157\u20138. https:\/\/doi.org\/10.1093\/ibd\/izab181.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1025_CR127","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1053\/j.gastro.2023.11.281","volume":"166","author":"SA Hassan","year":"2024","unstructured":"Hassan SA, Perry C, Flomenhoft D, et al. Upadacitinib as second- and third-line salvage therapy for refractory acute severe ulcerative colitis. Gastroenterology. 2024;166(3):S124-5. https:\/\/doi.org\/10.1053\/j.gastro.2023.11.281.","journal-title":"Gastroenterology"},{"issue":"5","key":"1025_CR128","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1365-2036.2007.03415.x","volume":"01","author":"A Kohn","year":"2007","unstructured":"Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;01(5):747\u201356. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03415.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1025_CR129","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","volume":"66","author":"G Syal","year":"2021","unstructured":"Syal G, Robbins L, Kashani A, et al. Hypoalbuminemia and bandemia predict failure of Infliximab rescue therapy in acute severe ulcerative colitis. Dig Dis Sci. 2021;66(1):199\u2013205. https:\/\/doi.org\/10.1007\/s10620-020-06177-7.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"1025_CR130","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/jgh.14072","volume":"33","author":"MC Choy","year":"2018","unstructured":"Choy MC, Seah D, Gorelik A, et al. Predicting response after Infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33(7):1347\u201352. https:\/\/doi.org\/10.1111\/jgh.14072.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1025_CR131","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","volume":"19","author":"R Battat","year":"2021","unstructured":"Battat R, Hemperly A, Truong S, et al. Baseline clearance of Infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol Mar. 2021;19(3):511\u2013e5186. https:\/\/doi.org\/10.1016\/j.cgh.2020.03.072.","journal-title":"Clin Gastroenterol Hepatol Mar"},{"key":"1025_CR132","doi-asserted-by":"publisher","unstructured":"Berinstein JA, Atkuri NA, Berinstein EM, et al. Predictors of 90-Day colectomy in hospitalized patients receiving Infliximab for acute severe ulcerative colitis at a tertiary care center. MedRxiv. 2022. 2022.05.16.22275155. https:\/\/doi.org\/10.1101\/2022.05.16.22275155.","DOI":"10.1101\/2022.05.16.22275155"},{"issue":"5","key":"1025_CR133","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cgh.2022.08.016","volume":"21","author":"KG Whaley","year":"2023","unstructured":"Whaley KG, Xiong Y, Karns R, et al. Multicenter cohort study of Infliximab pharmacokinetics and therapy response in pediatric acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2023;21(5):1338\u201347. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Supplement1","key":"1025_CR134","doi-asserted-by":"publisher","first-page":"i196","DOI":"10.1093\/ecco-jcc\/jjae190.0096","volume":"19","author":"W Li","year":"2025","unstructured":"Li W, Suen C, Choy MC, Cheng K, et al. DOP057 early serum and faecal cytokines predict clinical outcomes in acute severe ulcerative colitis: results from PREDICT-UC. J Crohn\u2019s Colitis. 2025;19(Supplement1):i196\u2013196. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0096.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"1025_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s13017-021-00362-3","volume":"16","author":"B De Simone","year":"2021","unstructured":"De Simone B, Davies J, Chouillard E, et al. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg. 2021;(1):23. https:\/\/doi.org\/10.1186\/s13017-021-00362-3.","journal-title":"World J Emerg Surg"},{"issue":"7","key":"1025_CR136","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/DCR.0000000000002037","volume":"1","author":"SD Holubar","year":"2021","unstructured":"Holubar SD, Lightner AL, Poylin V, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of ulcerative colitis. Dis Colon Rectum. 2021;1(7):783\u2013804. https:\/\/doi.org\/10.1097\/DCR.0000000000002037.","journal-title":"Dis Colon Rectum"},{"key":"1025_CR137","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_175_16","volume":"7","author":"H Khazraei","year":"2018","unstructured":"Khazraei H, Bananzadeh A, Hosseini SV. Early outcome of patient with ulcerative colitis who received high dose of steroid and underwent two staged total proctocolectomy. Adv Biomed Res. 2018;7:11. https:\/\/doi.org\/10.4103\/abr.abr_175_16.","journal-title":"Adv Biomed Res"},{"issue":"1","key":"1025_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72466-0","volume":"14","author":"M Brunner","year":"2024","unstructured":"Brunner M, Brandl M, Denz A, et al. 2-stage and 3-stage restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis show comparable short- and long-term outcomes. Sci Rep. 2024;(1):22807. https:\/\/doi.org\/10.1038\/s41598-024-72466-0.","journal-title":"Sci Rep"},{"issue":"3","key":"1025_CR139","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00384-018-03221-x","volume":"34","author":"GC Lee","year":"2019","unstructured":"Lee GC, Deery SE, Kunitake H, et al. Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. Int J Colorectal Dis. 2019;34(3):491\u20139. https:\/\/doi.org\/10.1007\/s00384-018-03221-x.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"1025_CR140","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/DCR.0000000000001276","volume":"62","author":"IL Leeds","year":"2019","unstructured":"Leeds IL, Sundel MH, Gabre-Kidan A, et al. Outcomes for ulcerative colitis with delayed emergency colectomy are worse when controlling for preoperative risk factors. Dis Colon Rectum. 2019;62(5):600\u20137. https:\/\/doi.org\/10.1097\/DCR.0000000000001276.","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"1025_CR141","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s11605-017-3538-3","volume":"21","author":"IL Leeds","year":"2017","unstructured":"Leeds IL, Truta B, Parian AM, et al. Early surgical intervention for acute ulcerative colitis is associated with improved postoperative outcomes. J Gastrointest Surg. 2017;21(10):1675\u201382. https:\/\/doi.org\/10.1007\/s11605-017-3538-3.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"1025_CR142","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","volume":"3","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;3(6):1187\u2013224. https:\/\/doi.org\/10.14309\/ajg.0000000000003463.","journal-title":"Am J Gastroenterol"},{"key":"1025_CR143","doi-asserted-by":"publisher","unstructured":"Feuerstein JD, Cheifetz AS. Management of inpatient inflammatory bowel disease: a comprehensive handbook. 1st ed.\u00a0New York:\u00a0Springer; 2021.\u00a0https:\/\/doi.org\/10.1007\/978-1-0716-1987-2.","DOI":"10.1007\/978-1-0716-1987-2"},{"issue":"7","key":"1025_CR144","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41395-018-0057-0","volume":"113","author":"I Ordas","year":"2018","unstructured":"Ordas I, Domenech E, Manosa M, et al. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: nationwide multicenter study of the GETECCU ENEIDA registry. Am J Gastroenterol. 2018;113(7):1009\u201316. https:\/\/doi.org\/10.1038\/s41395-018-0057-0.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1025_CR145","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00384-017-2836-2","volume":"32","author":"J Gu","year":"2017","unstructured":"Gu J, Stocchi L, Ashburn J, Remzi FH. Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis. Int J Colorectal Dis. 2017;32(8):1215\u201322. https:\/\/doi.org\/10.1007\/s00384-017-2836-2.","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"1025_CR146","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/codi.12267","volume":"15","author":"J Gu","year":"2013","unstructured":"Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Colorectal Dis. 2013;15(9):1123\u20139. https:\/\/doi.org\/10.1111\/codi.12267.","journal-title":"Colorectal Dis"},{"issue":"4","key":"1025_CR147","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/gutjnl-2017-315521","volume":"68","author":"C Eriksson","year":"2019","unstructured":"Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut. 2019;68(4):623\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2017-315521.","journal-title":"Gut"},{"issue":"8","key":"1025_CR148","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/MIB.0000000000000780","volume":"22","author":"A Afzali","year":"2016","unstructured":"Afzali A, Park CJ, Zhu K, et al. Preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1887\u201395. https:\/\/doi.org\/10.1097\/MIB.0000000000000780.","journal-title":"Inflamm Bowel Dis"},{"key":"1025_CR149","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/ceg.s4512","volume":"2","author":"L Vogelaar","year":"2009","unstructured":"Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101\u20139. https:\/\/doi.org\/10.2147\/ceg.s4512.","journal-title":"Clin Exp Gastroenterol"},{"key":"1025_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.01.032","author":"C Larson","year":"2025","unstructured":"Larson C, Berinstein JA, Tedesco N, et al. Postoperative outcomes in Tofacitinib-treated patients with acute severe ulcerative colitis undergoing colectomy. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.01.032.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1025_CR151","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.gastro.2022.03.057","volume":"163","author":"BL Cohen","year":"2022","unstructured":"Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology. 2022;163(1):204\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.057.","journal-title":"Gastroenterology"},{"issue":"10","key":"1025_CR152","doi-asserted-by":"publisher","first-page":"CD013256","DOI":"10.1002\/14651858.CD013256.pub2","volume":"24","author":"CC Law","year":"2020","unstructured":"Law CC, Bell C, Koh D, Bao Y, Jairath V, Narula N. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev Oct. 2020;24(10):CD013256. https:\/\/doi.org\/10.1002\/14651858.CD013256.pub2.","journal-title":"Cochrane Database Syst Rev Oct"},{"key":"1025_CR153","doi-asserted-by":"publisher","unstructured":"Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Aug. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51(8):1202-7; discussion 1207-10. https:\/\/doi.org\/10.1007\/s10350-008-9364-7","DOI":"10.1007\/s10350-008-9364-7"},{"issue":"5","key":"1025_CR154","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","volume":"204","author":"CR Selvasekar","year":"2007","unstructured":"Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956\u201362. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.12.044.","journal-title":"J Am Coll Surg"},{"issue":"9","key":"1025_CR155","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ecco-jcc\/jjad051","volume":"20","author":"MG Fadel","year":"2023","unstructured":"Fadel MG, Geropoulos G, Warren OJ, et al. Risks factors associated with the development of Crohn\u2019s disease after ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis. 2023;20(9):1537\u201348. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad051.","journal-title":"J Crohns Colitis"},{"key":"1025_CR156","doi-asserted-by":"publisher","unstructured":"Reijntjes M, de Jong D, Wessels E, et al. Crohn\u2019s disease of the ileoanal pouch: a high rate of potential overdiagnoses. Inflamm Bowel Dis. 2024(10). https:\/\/doi.org\/10.1093\/ibd\/izad228.","DOI":"10.1093\/ibd\/izad228"},{"issue":"10","key":"1025_CR157","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.dld.2008.03.014","volume":"40","author":"A Aratari","year":"2008","unstructured":"Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the Infliximab era. Dig Liver Dis. 2008;40(10):821\u20136. https:\/\/doi.org\/10.1016\/j.dld.2008.03.014.","journal-title":"Dig Liver Dis"},{"issue":"11","key":"1025_CR158","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.15751","volume":"51","author":"R Salameh","year":"2020","unstructured":"Salameh R, Kirchgesner J, Allez M, et al. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther. 2020;51(11):1096\u2013104. https:\/\/doi.org\/10.1111\/apt.15751.","journal-title":"Aliment Pharmacol Ther"},{"key":"1025_CR159","doi-asserted-by":"publisher","unstructured":"Narula N, Hamam H, Peerani F, et al. Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for postdischarge corticosteroid-free clinical remission and endoscopic improvement. Am J Gastroenterol. 2024(9). https:\/\/doi.org\/10.14309\/ajg.0000000000002860.","DOI":"10.14309\/ajg.0000000000002860"},{"issue":"Supplement1","key":"1025_CR160","doi-asserted-by":"publisher","first-page":"i267","DOI":"10.1093\/ecco-jcc\/jjae190.0140","volume":"19","author":"C Bravo","year":"2025","unstructured":"Bravo C, Frias-Gomes C, Blesl A, et al. DOP101 maintaining remission after an episode of steroid-responsive acute severe ulcerative colitis: what is the best strategy? J Crohn\u2019s Colitis. 2025;19(Supplement1):i267\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0140.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1025_CR161","doi-asserted-by":"publisher","unstructured":"Amiot A, Seksik P, Meyer A, et al. Top-down Infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial. Gut. 2025(2). https:\/\/doi.org\/10.1136\/gutjnl-2024-333281.","DOI":"10.1136\/gutjnl-2024-333281"},{"key":"1025_CR162","doi-asserted-by":"publisher","unstructured":"Honap S, Jairath V, Sands BE, et al. Acute severe ulcerative colitis: an international Delphi consensus on clinical trial design and endpoints. Clin Gastroenterol Hepatol Dec. 2024;15. https:\/\/doi.org\/10.1016\/j.cgh.2024.10.029.","DOI":"10.1016\/j.cgh.2024.10.029"},{"key":"1025_CR163","doi-asserted-by":"publisher","unstructured":"Taft TH, McGarva J, Omprakash TA, et al. Hospitalization experiences and post-traumatic stress in inflammatory bowel disease: opportunities for change. Inflamm Bowel Dis. 2023(5). https:\/\/doi.org\/10.1093\/ibd\/izac148.","DOI":"10.1093\/ibd\/izac148"},{"key":"1025_CR164","doi-asserted-by":"publisher","unstructured":"Taft TH, Bedell A, Craven MR, Guadagnoli L, Quinton S, Hanauer SB. Initial assessment of post-traumatic stress in a US cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2019(9). https:\/\/doi.org\/10.1093\/ibd\/izz032.","DOI":"10.1093\/ibd\/izz032"},{"issue":"10","key":"1025_CR165","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1007\/s10620-024-08633-0","volume":"69","author":"D Romain","year":"2024","unstructured":"Romain D, Larson C, Kathuria P, et al. Understanding the perspectives and experiences of patients with acute severe ulcerative colitis in the hospital: a qualitative analysis. Dig Dis Sci. 2024;69(10):3690\u2013700. https:\/\/doi.org\/10.1007\/s10620-024-08633-0.","journal-title":"Dig Dis Sci"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01025-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:01:49Z","timestamp":1767826909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01025-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":165,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01025-y","relation":{},"ISSN":["1534-312X"],"issn-type":[{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}